Close

Benefit-Risk: BIO Comments on Benefit-Risk Assessments in Drug Regulatory Decision-Making

Dear Sir/Madam: ...

BIO Statement on Senate GOP Tax Reform Proposal

Washington, DC (November 10, 2017) – Biotechnology Innovation Organization (BIO) Senior Vice President of Communications Kenneth Lisaius released the following statement regarding the Senate GOP tax reform proposal.

BIO Submits Comments Re: HHS Draft Strategic Plan FY 2018-2022

BIO submitted comments in response to the Health and Human Services (HHS/the Agency) Draft Strategic Plan for Fiscal Years 2018-2022. BIO strongly supports HHS’ mission to enhance the health and well-being of Americans, by providing for effective health and human services and by fostering sound, sustained advances in the science of underlying medicine, public health, and social services; and the associated strategic planning process.

BIO Submits Comments Re: USP Drug Classification System, Second Round of Public Comments

BIO submitted comments to the U.S. Pharmacopeial Convention (USP) Healthcare Quality and Safety Expert Committee (Expert Committee) in response to the second round of public comment on the USP Drug Classification System (USP DC), released September 25, 2017. In response to the USP DC, BIO offers comments consistent with our comprehensive comments on the draft Version 7.0 Medicare Model Guidelines (MMG) and comments on last year’s draft USP DC, both of which are included as appendices for the Expert Committee’s reference. Our comments, as follows, also correspond to the call for additional feedback on how to make the USP DC more user friendly as expressed on the open-mic web meeting.

BIO Statement on USDA Withdrawal of 340 Biotech Rules

The U.S. Department of Agriculture’s (USDA) Animal and Plant Health Inspection Service (APHIS) today announced its intention to withdraw its proposed revisions to regulations (7 CFR part 340) governing agricultural biotechnology.  The Biotechnology Innovation Organization (BIO) issued the following statement in response:

BIO Releases Plan to Unleash Innovation in Fight against Opioid Abuse and Addiction

Washington, DC (November 2, 2017) – The Biotechnology Innovation Organization (BIO) today released a set of priorities for unleashing the power of innovation to develop solutions to prescription opioid abuse and addiction. Many of BIO’s priorities align with recommendations put forth yesterday by the President’s Commission on Combating Drug Addiction and the Opioid Crisis, including proposals to ensure that patients have comprehensive access to appropriate treatments, and increasing support for basic research to improve our understanding of the biology of pain and addiction. 

BIO Statement on House GOP Tax Reform Bill

Washington, DC (November 2, 2017) – Biotechnology Innovation Organization (BIO) Jim Greenwood released the following statement today regarding the Tax Cuts and Jobs Act: “BIO applauds Chairman Brady and the House Ways & Means Committee for their dedication to pro-growth tax reform. Tax reform presents a unique, historic opportunity to stimulate American investment, support job creation, and promote life-saving innovation. The Tax Cuts and Jobs Act would lower America’s corporate tax rate, maintain the R&D Tax Credit, and move the U.S. to a territorial tax system, which will make the U.S. more competitive on the world stage and support domestic manufacturing and job creation. This reform is vital to maintaining American leadership in biotechnology innovation.

BIO Applauds MLP Parity Act, Thanks Senate and House Sponsors

The bipartisan Master Limited Partnerships Parity Act of 2017 would level the playing field in the tax code by giving investors in renewable energy projects access to a decades-old corporate structure with a tax advantage now available only to fossil fuel projects.

BIO, Member Companies Ask Congress to Reauthorize Section 9003 Program in Farm Bill

BIO and 66 renewable chemical producers today asked leaders of the House and Senate Committees on Agriculture to reauthorize the Farm Bill’s Biorefinery, Renewable Chemical, and Biobased Manufacturing Assistance Program (Section 9003) and “fully and unconditionally allow renewable chemical standalone manufacturing facilities” to receive Section 9003 Program loan guarantees without requiring production of advanced biofuels.

BIO Applauds Senate Introduction of Renewable Chemicals Tax Credit

BIO thanks Sen. Debbie Stabenow (D-MI) and co-sponsors Sens. Tammy Baldwin (D-WI), Susan Collins (R-ME), Chris Coons (D-DE), and Al Franken (D-MN) for introducing the Renewable Chemicals Act of 2017 (S.1980), which would create a targeted, short-term tax credit for production of qualifying renewable chemicals or investment in production facilities.